11.56
+0.08(+0.70%)
Currency In USD
| Previous Close | 11.48 |
| Open | 11.55 |
| Day High | 11.62 |
| Day Low | 11.55 |
| 52-Week High | 11.88 |
| 52-Week Low | 6.69 |
| Volume | 12,562 |
| Average Volume | 1.69M |
| Market Cap | 3.63B |
| PE | 1,156 |
| EPS | 0.01 |
| Moving Average 50 Days | 10.19 |
| Moving Average 200 Days | 8.62 |
| Change | 0.08 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $770.15 as of November 11, 2025 at a share price of $11.56. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,778.85 as of November 11, 2025 at a share price of $11.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
GlobeNewswire Inc.
Oct 29, 2025 8:05 PM GMT
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segmentBRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announ
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceutica
Amneal to Report Third Quarter 2025 Results on October 30, 2025
GlobeNewswire Inc.
Sep 30, 2025 8:05 PM GMT
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial result